MUNICH, 09-Jan-2018 — /EuropaWire/ — Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system, in which the body’s own immune cells attack the fatty, insulating myelin sheath surrounding nerve fibers. The regeneration of intact myelin … Read the full press release
GENEVA, 08-Jun-2016 — /EuropaWire/ — TESTmyBRAIN (Switzerland) has opened its first center of Functional Neurology in Europe. This non-invasive therapy (no medication, no surgery) coming from the United States helps patients suffering from migraines, concussions, strokes, AD/HD, Parkinson disease, Alzheimer, … Read the full press release
Posted in Education, Germany, Healthcare, Netherlands, News, Sports, Switzerland, United Kingdom
Tagged ADHD, Alzheimer, central nervous system, Concussions, dizziness, headaches, migraines, Mr. Claude Martinet, Parkinson, stroke, Switzerland, TESTmyBRAIN, testmybrain.ch
Cordoba, Spain, 12-6-2013 — /europawire.eu/ — VivaCell Biotechnology España S.L., Cordoba, Spain today announced that it has entered into joint Research Collaboration and Commercialization Agreements with Aphios Corporation, USA, to develop therapeutics for multiple sclerosis and other neurodegenerative diseases of the central … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Spain
Tagged Aphios Corporation, biotech company, biotech development, biotech pharma companies, biotechnology, cannabinoid receptor, cannabinoids, central nervous system, CNS and neurological disorders, Cordoba, endocannabinoid system, multiple sclerosis, neurodegenerative diseases, novel class of compounds, therapeutics for multiple sclerosis, VivaCell Biotechnology, VivaCell Biotechnology España S.L.
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
